Welcome to our dedicated page for Amarin SEC filings (Ticker: AMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-trial tables, patent litigation updates, and regulatory risk factors make Amarin’s disclosures anything but light reading. Whether you’re hunting for the next VASCEPA milestone or tracking how REDUCE-IT data impacts guidance, the critical details are buried inside hundreds of pages of SEC language.
Stock Titan solves this challenge by turning each document into a clear briefing. Our AI delivers Amarin SEC filings explained simply, flags Amarin insider trading Form 4 transactions the moment they post, and links trial results to revenue guidance—all in one dashboard. Need the Amarin annual report 10-K simplified or an Amarin 8-K material events explained alert? We break down the jargon, highlight patent terms, and surface risk disclosures so you can focus on decisions, not document hunts.
- Real-time alerts for every Amarin Form 4 insider transactions real-time filing
- Concise takeaways from each Amarin quarterly earnings report 10-Q filing plus side-by-side Amarin earnings report filing analysis
- Immediate visibility into board pay inside the Amarin proxy statement executive compensation
From Amarin executive stock transactions Form 4 to pipeline-critical disclosures, our expert layer translates accounting notes, R&D cost lines, and intellectual-property timelines into plain English. If you’re understanding Amarin SEC documents with AI for the first time or fine-tuning a discounted-cash-flow model, Stock Titan equips you with the insights and speed required to act confidently.
Amarin Corporation plc (AMRN) filed an 8-K announcing two material events dated 20-24 June 2025.
1. Exclusive European license for VAZKEPA. On 20 June 2025 the company, through subsidiary Amarin Pharmaceuticals Ireland Limited, executed a 15-year license & supply agreement with Recordati Industria Chimica e Farmaceutica S.p.A. covering 59 European countries. Amarin will receive: (i) a $25 million upfront cash payment; (ii) up to $150 million in commercial milestone payments; and (iii) tiered royalties on Recordati’s net sales of VAZKEPA. The contract automatically renews for additional 15-year terms provided Recordati commercialises the product in at least one country before the initial term expires. Amarin retains full rights to VAZKEPA outside the licensed territory.
2. Global restructuring & cost reduction. On 24 June 2025 Amarin announced a restructuring programme, primarily focused on its European commercial operations. Management expects the initiative to trim annual operating expenses by roughly $70 million, with substantial completion targeted by 30 June 2026. The plan will trigger $30-$37 million in one-time charges, almost entirely cash outflows for termination benefits and related costs, to be recorded in Q2 2025 and largely paid by 31 December 2025. The company cautions that actual costs may differ materially from current estimates and that additional expenses could arise.
Strategic implications. The license immediately monetises European rights, provides non-dilutive capital, shifts commercial execution risk to Recordati, and maintains long-term participation through royalties. Simultaneously, the restructuring initiative reduces Amarin’s fixed cost base, potentially improving EBITDA break-even timelines. However, the company relinquishes direct control over a key geography and incurs material near-term cash charges. Future revenue visibility will depend on Recordati’s commercial success and milestone achievement.
FAQ
What is the current stock price of Amarin (AMRN)?
What is the market cap of Amarin (AMRN)?
What is the primary focus of Amarin Corporation?
What is VASCEPA and why is it significant?
How does Amarin differentiate itself in the biotechnology sector?
What clinical evidence supports Amarin's therapeutic approach?
How does Amarin maintain its competitive advantage in global markets?
What role does lipid science play in Amarin's product development?
How does Amarin protect its intellectual property?
What impact does Amarin aim to have on cardiovascular disease management?
